Geometry Dash APK Hill Climb Racing APK
36.2 F
New York
Sunday, January 16, 2022

Odds are Stacked Against Novavax, Inc. (NASDAQ:NVAX)

Must read

Medmen Enterprises Inc (OTCMKTS:MMNFF) Pulls Back From Highs as Buzz Cools Off

Among the sectors which have bounced back in 2021, the cannabis sector is one of considerable interest since it had been in...

VirtualArmour International Inc (OTCMKTS:VTLR) Jumps Another 250% This Week

Not every move in the stock market can always be explained and hence, investors are often rightly confused when a stock records...

Ozop Energy Solutions Inc (OZSC) is Riding a Green Wave of Momentum

Investors who are looking for fresh opportunities in rising stocks may have a lot to choose from at this point but it...

Drone Delivery Canada Corp (OTCMKTS:TAKOF) is Soaring after Roadmap Update

The drone industry has grown at a remarkable rate over the past five years or so and hence, it is no surprise...

ResVax Failure Ramifications

Novavax, Inc. (NASDAQ:NVAX) is at a crucial moment as its ResVax influenza vaccine failed. NVAX missed on the primary endpoint for the drug and the stock fell hard going from $2.13 to now just above $0.60. The reason here is obvious, but there may still be some ways NVAX could salvage ResVax.

“Although we are disappointed to announce that the Prepare trial did not meet the prespecified criterion for the primary endpoint, ResVax did, however, demonstrate statistically significant efficacy against hospitalization associated with RSV lower respiratory tract infection at 44% with the lower band of confidence of nearly 20%,” said, President and CEO Stan Erck. This announcement leaves NVAX with really three options to choose from: the vaccine’s ability to hit on key secondary endpoints may be enough to convince regulators to approve the vaccine outright. Next, regulators might approve the vaccine based on these promising hints of efficacy in severe RSV cases, but with the understanding that Novavax would conduct a post-licensure trial. Lastly, regulators may require the company to undertake yet another late-stage trial prior to granting approval.

Novavax, Inc. (NASDAQ:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax™, its RSV vaccine for infants via maternal immunization, and NanoFlu™, its quadrivalent influenza nanoparticle vaccine. Novavax’ proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

According to NVAX, ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant. It is being developed to protect infants from RSV disease via maternal immunization, which may offer the best method of protection from RSV disease in infants through the first months of life. In February 2019, Novavax announced top-line data from Prepare™, a global Phase 3 clinical trial in 4,636 pregnant women, at least 3,000 of whom have received the vaccine, and their infants. Prepare is supported by an $89.1 million grant from the Bill & Melinda Gates Foundation (BMGF).

Find out when $NVAX stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Digesting the Big Blow

All of these discussions take time to set up, but we are pressing to have them as soon as reasonably possible, hopefully in the second quarter or early third quarter of this year. We will provide an update on our progress at the appropriate time. In parallel, we continue to assess the best partner for our ResVax program and perhaps multiple partners, with capabilities in different geographies,” Erck added in the call.

This news was obviously a crushing blow to the stock and its beleaguered shareholders. Primary concern is cash to keep the company up and running. CFO John Trizzino noted that Novavax raised around $41 million in cash in the first quarter of 2019 by selling additional shares. He said that the company took this step even though its stock price has been beaten down because management “concluded that it was more important to add to our balance sheet as we negotiate with potential partners and regulators.”

Novavax, Inc. (NASDAQ:NVAX) has a market cap of $226.34M and a current float of 378.41M. We expect the company to make some drastic moves to shore up cash flow, but this stock is no longer for the feint of heart. For continuing coverage on shares of Novavax stock, as well as our other breakout picks, sign up for our free newsletter today and get our next hot stock pick!

Disclosure: we hold no position in $NVAX, either long or short, and we have not been compensated for this article.


Latest article

iQSTEL Inc (OTCMKTS:IQST) Stock Makes a Big Move: Jumps 45% In a Week

In the past week, iQSTEL Inc (OTCMKTS: IQST) has emerged as a point of focus among a large number of investors and...

HUMBL Inc (OTCMKTS:HMBL) Stock Sees Big Bounce After Recent Slump

Since the beginning of 2021, HUMBL Inc (OTCMKTS:HMBL) had been one of the major movers from among penny stocks and had come into...

Dividend Stocks to Buy Now

A classic mistake that investors make when looking for dividend stocks is to just go for the biggest dividend yield. It makes...

88 Energy Ltd (OTCMKTS:EEENF) Stock Surges 40% But Can’t Hold Gains

The oil and gas company 88 Energy Ltd (OTCMKTS:EEENF) seems to have come back on to the radars of investors over the...

Net Savings Link Inc (OTCMKTS:NSAV) Stock is Getting Pummeled Again

Nowadays there are plenty of options for investors when it comes to making investments in the cryptocurrency and...
Şehirler arası nakliyat ve Şehirler arası taşımacılık konusunda en uygun fiyatlar ve en kaliteli hizmet.
ofis taşıma firmaları ve ofis taşıma konusunda en uygun fiyatlar ve en kaliteli hizmet.
SmsVerifyer.com Affordable best sms verification service